Cellceutix Cancer Compound: Crunching the Numbers

WILMINGTON, Mass.--(BUSINESS WIRE)--May 29, 2008 - Cellceutix (OTCBB: CTIX) President and CSO Dr. Krishna Menon, lead developer of Eli Lilly (NYSE: LLY) cancer compounds Gemzar(R) and Alimta(R), recently conducted a pooled analysis of animal tests of Cellceutix's lead candidate, Kevetrin(TM), against Head and Neck cancer SCC-15, a squamous cell carcinoma. The results demonstrated that compared with controls, Kevetrin as solo treatment produced tumor reduction of 31.5% and when administered sequentially with radiation produced tumor reduction of 73.7%. The results offer hope against the sixth most common cancer globally, but one that headlines few pipelines.

Dr. Menon's recent analysis pooled the results of three experiments conducted with the same protocol at three different locations, KARD Scientific in Wilmington, MA, Toxicone, in Hyderabad, India, and the University of British Columbia. In each of the experiments, radiation was administered alone, and Kevetrin was administered alone and sequentially with radiation in nude mice with human squamous cell carcinoma SCC-15. In these individual experiments, both Kevetrin and Kevetrin combined with radiation showed statistically significant tumor reduction compared to the controls (p less than .003 using the Student T-test). The results of the experiments at Toxicone and the University of British Columbia confirmed the findings of Dr. Menon's original experiment at KARD. In the pooled analysis, as well, both Kevetrin and Kevetrin administered sequentially with radiation demonstrated statistically significant tumor reduction compared with the controls (p less than .003 using the Student T-test.) (Radiation alone also showed a statistically significant tumor reduction of 36.8% compared to controls.) For a more detailed summary of the results, please visit Cellceutix.com.

About Cellceutix

A preclinical cancer and anti-inflammatory drug developer, Cellceutix owns the rights to six potential pharmaceutical products, including four invented by its President and CSO Dr. Krishna Menon, RCM, PhD, VMD, a 1999 Eli Lilly (NYSE: LLY) Employee of the Year. Cellceutix is chaired and CEO'd by George Evans, JD, MBA, a former Pfizer (NYSE: PFE) Associate General Counsel and Senior VP, General Counsel Human Health (Pfizer's prescription drug division).

This press release may contain forward-looking statements. Cellceutix wants to remind readers that actual results may differ and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For more information, please visit Cellceutix.com and review Company filings with the Securities and Exchange Commission.

Kevetrin has not been studied in humans. Readers should be aware that positive results in animal tests do not necessarily mean that a drug will work in humans.

Contact

E Unum Pluribus LLC
Carl Waynberg, CEO, 877-997-4747
cellceutix@eunumpluribus.com

Posted: May 2008

Comments